These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17996426)

  • 21. Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis.
    Ghiselli R; Giacometti A; Cirioni O; Mocchegiani F; Orlando F; Silvestri C; Di Matteo F; Abbruzzetti A; Scalise G; Saba V
    Crit Care Med; 2008 Jan; 36(1):240-5. PubMed ID: 18090372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
    Banic S
    APMIS; 2006 Jan; 114(1):3-9. PubMed ID: 16499654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy of automated and manual systems for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam.
    Gagliotti C; Sarti M; Sabia C; Gargiulo R; Rossolini GM; Carillo C; Cassani C; Cipolloni AP; Pedna F; Rossi MR; Incerti SS; Testa G; Venturelli C; Moro ML
    New Microbiol; 2011 Jan; 34(1):97-9. PubMed ID: 21344153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panels.
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2005 May; 52(1):67-9. PubMed ID: 15878446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
    Nord CE
    J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
    [No Abstract]   [Full Text] [Related]  

  • 26. Protective effect of citropin 1.1 and tazobactam-piperacillin against oxidative damage and lethality in mice models of gram-negative sepsis.
    Ghiselli R; Silvestri C; Cirioni O; Kamysz W; Orlando F; Calcinari A; Kamysz E; Casteletti S; Rimini M; Tocchini M; Giacometti A; Guerrieri M
    J Surg Res; 2011 Dec; 171(2):726-33. PubMed ID: 20605608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The sensitivity of clinical isolates of anaerobic species to piperacillin-tazobactam and other antimicrobial agents.
    Namavar F; Severin WP; Stobberingh E; Smeets T; MacLaren DM
    J Antimicrob Chemother; 1994 Sep; 34(3):415-9. PubMed ID: 7829416
    [No Abstract]   [Full Text] [Related]  

  • 28. Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots.
    Moet GJ; Watters AA; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):319-22. PubMed ID: 19822271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superior in vitro activity of ertapenem and piperacillin/tazobactam against recent clinical isolates of Proteus mirabilis from intra-abdominal infections (SMART 2009-2010).
    Hawser SP
    Int J Antimicrob Agents; 2011 Aug; 38(2):186-7. PubMed ID: 21632217
    [No Abstract]   [Full Text] [Related]  

  • 30. Role of the culture medium in porin expression and piperacillin-tazobactam susceptibility in Escherichia coli.
    Pinet E; Franceschi C; Davin-Regli A; Zambardi G; Pagès JM
    J Med Microbiol; 2015 Nov; 64(11):1305-1314. PubMed ID: 26242994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/tazobactam and thirteen other antimicrobial agents.
    Simor AE; Louie L; Louie M
    Eur J Clin Microbiol Infect Dis; 1994 Jun; 13(6):521-3. PubMed ID: 7957281
    [No Abstract]   [Full Text] [Related]  

  • 32. Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?
    Kundrapu S; Sunkesula VC; Jury LA; Cadnum JL; Nerandzic MM; Musuuza JS; Sethi AK; Donskey CJ
    BMC Infect Dis; 2016 Apr; 16():159. PubMed ID: 27091232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating the ototoxicity of topical piperacillin-tazobactam.
    Jang CH; Park H; Cho YB; Choi CH
    Int J Pediatr Otorhinolaryngol; 2008 Dec; 72(12):1815-21. PubMed ID: 18845345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131.
    Rodríguez-Villodres Á; Ortiz de la Rosa JM; Álvarez-Marín R; Pachón J; Aznar J; Lepe JA; Smani Y
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061749
    [No Abstract]   [Full Text] [Related]  

  • 35. Tachyplesin III and granulocyte-colony stimulating factor enhance the efficacy of tazobactam/piperacillin in a neutropenic mouse model of polymicrobial peritonitis.
    Cirioni O; Ghiselli R; Kamysz W; Orlando F; Silvestri C; Mocchegiani F; Di Matteo F; Kamysz E; Riva A; Rocchi M; Saba V; Scalise G; Giacometti A
    Peptides; 2008 Jan; 29(1):31-8. PubMed ID: 18068869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combined effect of 6/N,N-1',6'-hexyleneformamidine-penicillanic acid (preparation HX) and selected beta-lactam antibiotics on E. coli and Salmonella. I. Studies in vitro].
    Zaremba M; Zukowska-Nytko K; Borowski J
    Med Dosw Mikrobiol; 1982; 34(1-2):27-36. PubMed ID: 6292594
    [No Abstract]   [Full Text] [Related]  

  • 37. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.
    Patel GW; Patel N; Lat A; Trombley K; Enbawe S; Manor K; Smith R; Lodise TP
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):236-40. PubMed ID: 19500529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA.
    Jones RN; Sader HS; Flamm RK; Watters AA
    Diagn Microbiol Infect Dis; 2013 May; 76(1):110-2. PubMed ID: 23490010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro evaluation of new beta-lactamase inhibitor: YTR830H and derivatives.
    Ishida N; Higashitani F; Hanehara C; Uji T; Inoue M; Mitsuhashi S
    J Chemother; 1989 Jul; 1(4 Suppl):88-9. PubMed ID: 16312318
    [No Abstract]   [Full Text] [Related]  

  • 40. Sub-Inhibitory Concentration of Piperacillin-Tazobactam May be Related to Virulence Properties of Filamentous Escherichia coli.
    de Andrade JP; de Macêdo Farias L; Ferreira JF; Bruna-Romero O; da Glória de Souza D; de Carvalho MA; dos Santos KV
    Curr Microbiol; 2016 Jan; 72(1):19-28. PubMed ID: 26364189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.